ZA202406196B - Crf2 receptor agonists and their use in therapy - Google Patents
Crf2 receptor agonists and their use in therapyInfo
- Publication number
- ZA202406196B ZA202406196B ZA2024/06196A ZA202406196A ZA202406196B ZA 202406196 B ZA202406196 B ZA 202406196B ZA 2024/06196 A ZA2024/06196 A ZA 2024/06196A ZA 202406196 A ZA202406196 A ZA 202406196A ZA 202406196 B ZA202406196 B ZA 202406196B
- Authority
- ZA
- South Africa
- Prior art keywords
- therapy
- sarcopenia
- receptor agonists
- obesity
- crf2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22158188.7A EP4234574A1 (en) | 2022-02-23 | 2022-02-23 | Crf2 receptor agonists and their use in therapy |
| PCT/EP2023/054317 WO2023161229A1 (en) | 2022-02-23 | 2023-02-21 | Crf2 receptor agonists and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202406196B true ZA202406196B (en) | 2025-03-26 |
Family
ID=80819682
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/06196A ZA202406196B (en) | 2022-02-23 | 2024-08-13 | Crf2 receptor agonists and their use in therapy |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20260001928A1 (https=) |
| EP (2) | EP4234574A1 (https=) |
| JP (1) | JP2025508820A (https=) |
| KR (1) | KR20240153565A (https=) |
| CN (1) | CN118843638A (https=) |
| AU (1) | AU2023224327A1 (https=) |
| CA (1) | CA3247142A1 (https=) |
| ES (1) | ES3063881T3 (https=) |
| HR (1) | HRP20260115T1 (https=) |
| IL (1) | IL314055A (https=) |
| IS (1) | IS050770A (https=) |
| MX (1) | MX2024010296A (https=) |
| PL (1) | PL4482578T3 (https=) |
| WO (1) | WO2023161229A1 (https=) |
| ZA (1) | ZA202406196B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025104264A1 (en) * | 2023-11-17 | 2025-05-22 | Gubra A/S | Hcrhr2 selective polypeptides |
| WO2026064495A1 (en) * | 2024-09-20 | 2026-03-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
| WO2026064486A1 (en) * | 2024-09-20 | 2026-03-26 | Neurocrine Biosciences, Inc. | Chemically modified peptides and use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008047241A2 (en) * | 2006-10-16 | 2008-04-24 | Conjuchem Biotechnologies Inc. | Modified corticotropin releasing factor peptides and uses thereof |
| JOP20170153A1 (ar) | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| WO2019140030A1 (en) * | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| US20250243255A1 (en) * | 2020-08-19 | 2025-07-31 | Sanofi | Crf2 receptor agonists and their use in therapy |
-
2022
- 2022-02-23 EP EP22158188.7A patent/EP4234574A1/en not_active Withdrawn
-
2023
- 2023-02-21 AU AU2023224327A patent/AU2023224327A1/en active Pending
- 2023-02-21 MX MX2024010296A patent/MX2024010296A/es unknown
- 2023-02-21 US US18/839,784 patent/US20260001928A1/en active Pending
- 2023-02-21 HR HRP20260115TT patent/HRP20260115T1/hr unknown
- 2023-02-21 CN CN202380019995.3A patent/CN118843638A/zh active Pending
- 2023-02-21 CA CA3247142A patent/CA3247142A1/en active Pending
- 2023-02-21 ES ES23705580T patent/ES3063881T3/es active Active
- 2023-02-21 IL IL314055A patent/IL314055A/en unknown
- 2023-02-21 EP EP23705580.1A patent/EP4482578B1/en active Active
- 2023-02-21 PL PL23705580.1T patent/PL4482578T3/pl unknown
- 2023-02-21 KR KR1020247028787A patent/KR20240153565A/ko active Pending
- 2023-02-21 JP JP2024550131A patent/JP2025508820A/ja active Pending
- 2023-02-21 WO PCT/EP2023/054317 patent/WO2023161229A1/en not_active Ceased
-
2024
- 2024-08-13 ZA ZA2024/06196A patent/ZA202406196B/en unknown
- 2024-09-18 IS IS050770A patent/IS050770A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240153565A (ko) | 2024-10-23 |
| IS050770A (is) | 2024-10-15 |
| CN118843638A (zh) | 2024-10-25 |
| EP4482578C0 (en) | 2025-12-24 |
| ES3063881T3 (en) | 2026-04-21 |
| EP4482578B1 (en) | 2025-12-24 |
| EP4482578A1 (en) | 2025-01-01 |
| IL314055A (en) | 2024-09-01 |
| HRP20260115T1 (hr) | 2026-03-13 |
| EP4234574A1 (en) | 2023-08-30 |
| JP2025508820A (ja) | 2025-04-10 |
| MX2024010296A (es) | 2024-09-18 |
| US20260001928A1 (en) | 2026-01-01 |
| WO2023161229A1 (en) | 2023-08-31 |
| AU2023224327A1 (en) | 2024-08-29 |
| PL4482578T3 (pl) | 2026-03-16 |
| CA3247142A1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202406196B (en) | Crf2 receptor agonists and their use in therapy | |
| ZA202301784B (en) | Crf2 receptor agonists and their use in therapy | |
| US12478617B2 (en) | Lipidated peptide inhibitors of interleukin-23 receptor | |
| JP7541600B2 (ja) | Ｇｉｐアゴニスト化合物及び方法 | |
| JP5755653B2 (ja) | ペプチド性ｇｌｐ−２アゴニスト | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| US20210032292A1 (en) | Treatments for Gastrointestinal Disorders | |
| JP2005532330A5 (https=) | ||
| JP4896728B2 (ja) | ブラジキニンｂ１受容体の拮抗薬 | |
| JP2004521123A5 (https=) | ||
| US20160175286A1 (en) | Selective at2 receptor agonists for use in treatment of cachexia | |
| JP2016519106A5 (https=) | ||
| US20180009849A1 (en) | Ghrelin analogues | |
| TW201804994A (zh) | 抗真菌劑 | |
| MX2023002522A (es) | Compuestos novedosos para usar en el tratamiento de enfermedades asociadas con la angiotensina ii. | |
| JP5319920B2 (ja) | ナトリウムおよび／またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための（ハロベンジルオキシ）ベンジルアミノ−プロパンアミドの使用 | |
| WO2020236690A9 (en) | Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes | |
| US11578112B2 (en) | Long-acting adrenomedullin derivative conjugated with Fc region of immunoglobulin | |
| US20140348942A1 (en) | Treatments for Gastrointestinal Disorders | |
| EP2460826A1 (en) | Motilin-like peptide compound having transmucosal absorbability imparted thereto | |
| CN117202938A (zh) | 变体Fc结构域及其用途 | |
| WO2019061812A1 (zh) | 氨基酸骨架类新型cxcr4拮抗剂及其制备与生物医学应用 | |
| CN100339079C (zh) | 取代的咪唑烷类化合物,其制备方法,其作为药物或诊断剂的用途以及含有取代的咪唑烷类化合物的药物 | |
| IL276474B2 (en) | Modified bisphenyl butanoic ester derivatives as nep inhibitors | |
| Samanta et al. | Ramipril poisoning rescued by naloxone and terlipressin |